Searchable abstracts of presentations at key conferences on calcified tissues

ba0003pp357 | Osteoporosis: treatment | ECTS2014

In postmenopausal women previously treated with an oral bisphosphonate and at higher risk of fracture, denosumab significantly increases bone mineral density compared with ibandronate and risedronate

Brown Jacques P , Bolognese Michael A , Ho Pei-Ran , Roux Christian , Bone Henry G , Bonnick Sydney L , van den Bergh Joop , Ferreira Irene , Ghelani Prayashi , Dakin Paula , Wagman Rachel B , Recknor Christopher

Low bone mineral density (BMD) is an important and modifiable risk factor for fracture in postmenopausal women with osteoporosis. Denosumab (DMAb) shows a stronger relationship between BMD increases and antifracture efficacy than oral bisphosphonate (BP) therapies. Subjects who remain at higher risk of fracture despite current BP therapy need treatment. In two studies, DMAb significantly increased BMD and decreased bone turnover markers vs a BP (ibandronate (IBN) or risedronat...

ba0004oc5 | (1) | ICCBH2015

Bivariate analyses of BMD and lean mass in children identifies variants with novel pleiotropic effects across six BMD loci and in the TOM1L2 locus

Medina-Gomez Carolina , Kemp John P , Heppe Denise H M , Tobias Jon H , Hofman Albert , Carola Zillikens M , Uitterlinden Andre G , Jaddoe Vincent W V , Evans David M , Rivadeneira Fernando

Background: Lean and bone mass are heritable traits with high phenotypic correlation (rho=0.44), likely reflecting the underlying mechanical and biochemical interactions between tissues.Aim: Estimate the shared heritability (genetic correlation) of both traits in children and identify genetic determinants displaying pleiotropic effects on lean mass and bone mass accrual.Methods: Participants make part of two prospective po...

ba0005oc1.1 | Clinical trials and osteoporosis treatment | ECTS2016

Efficacy of odanacatib in postmenopausal women with osteoporosis: subgroup analyses of data from the phase 3 long-term odanacatib fracture trial (LOFT)

Saag Kenneth G , Alexandersen Peter , Benhamou Claude-Laurent , Gilchrist Nigel , Halse Johan , Michael Lewiecki E. , Lippuner Kurt , McClung Michael , Shiraki Masataka , DaSilva Carolyn A , Verbruggen Nadia , Scott Boyd B , Lombardi Antonio

Odanacatib (ODN), a selective oral inhibitor of cathepsin K, is in development for the treatment of osteoporosis. In the primary efficacy analysis of the Phase 3, Long-Term ODN Fracture Trial (LOFT; NCT00529373), ODN significantly reduced fracture risk compared with placebo in postmenopausal women with osteoporosis. Pre-specified subgroup analyses evaluated the efficacy of ODN in patient subgroups.Women aged ≥65 years, without baseline radiographic...

ba0004p89 | (1) | ICCBH2015

Bone mineral density in solid cancer survivors: a cross sectional long-term follow-up study. A preliminary report

Latoch Eryk , Katarzyna Muszynska-Roslan , Kaminski Marcin Jakub , Panasiuk Anna , Sawicka-Zukowska Malgorzata , Konstantynowicz Jerzy , Krawczuk-Rybak Maryna

Objectives: Abnormal bone mass is one of the late effects which might affect childhood cancer survivors in their later life. There are a lot of studies assessing bone deficits in patients with blood cancer, however there is little research conducted on solid cancer survivors. The aim of this study was to determine the frequency of low bone mass in analyzed group and to assess the influence of time after the end of treatment.Methods: A cross-sectional stu...

ba0003pp97 | Cancer and bone: basic, translational and clinical | ECTS2014

TRAF2, but not TRAF6, regulates breast cancer induced osteoclastogenesis and osteolysis.

Peramuhendige Prabha , Marino Silvia , Mollat Patrick , Idris Aymen I.

Tumour necrosis factor receptor associated factors (TRAFs) play a key role in signal transduction in mammalian cells. Several members of the TRAF family have been identified but only TRAF2 and TRAF6 are implicated in the regulation of osteoclastogenesis. Here we studied the role of TRAF2 and TRAF6 in breast cancer induced bone cell activity and osteolysis. We observed that TRAF2, but not TRAF6, is highly expressed in the human MDA-MB-231 (MDA-231) bone-seeking breast cancer ce...

ba0003pp406 | Paediatric bone disease | ECTS2014

Early intervention with anti-resorptives is essential in OI: a longterm murine study

Raggio Cathleen , Marino Josephine , Doty Steve , Pleshko Nancy , Boskey Adele

The oim/oim mouse resembles type III OI. Our study mimics clinical questions: is RANK-Fc as efficacious as ALN in reducing fracture number? Is RANK-Fc safe to administer to children? Is there any advantage to receiving RANK-Fc treatment post adolescence, following no treatment or ALN treatment from infancy through adolescence?All animal work was done under an IACUC-approval. Mice – n=200, WT or oim/oim. Treatment spanned a...

ba0004p102 | (1) | ICCBH2015

Bone robusticity in two distinct skeletal dysplasias: an evaluation of the second metacarpal, a surrogate for bone strength

Marino Josephine , Jepsen Karl , Carter Erin , Raggio Cathleen

Radiographs of the second metacarpal are used to assess bone strength development in paediatric populations. Children with achondroplasia and osteogenesis imperfecta (OI) have known differences in bone strength. Details of how bone strength develops and compares within these populations to unaffected children are lacking. A data set for patients with achondroplasia and OI was established.A retrospective IRB-approved review of bone-age films (n=6...

ba0006p053 | (1) | ICCBH2017

Determinants of bone density in Duchenne muscular dystrophy

Broggi Francesca , Vai Silvia , Baranello Giovanni , Gorni Ksenja , D'Angelo Grazia , Pane Marika , Vita Gianluca , Bianchi Maria Luisa

Objectives: Low bone mineral density (BMD) and increased frequency of peripheral and vertebral fractures have been reported in boys with Duchenne muscular dystrophy (DMD), but studies on the determinants of low BMD are still very few. We are currently carrying out a multicenter, prospective study aimed to identify the characteristics of DMD boys with a higher risk of bone loss and fractures.Methods: Forty-two DMD boys (mean age 9.9±3.3 years) underw...

ba0002p36 | (1) | ICCBH2013

Vitamin D deficiency and its relationship to parathyroid hormone in morbidly obese adolescents prior to bariatric surgery

Censani Marisa , Stein Emily , Shane Elizabeth , Oberfield Sharon , McMahon Donald , Lerner Shulamit , Fennoy Ilene

Objectives: Obese adults commonly have vitamin D deficiency and secondary hyperparathyroidism prior to bariatric surgery. Whether similar metabolic abnormalities exist in morbidly obese adolescents is not known. This study investigated the prevalence of vitamin D deficiency and evaluated the relationship between vitamin D and parathyroid hormone (PTH) in morbidly obese adolescents undergoing evaluation for bariatric surgery.Methods: A cross-sectional stu...

ba0001pp500 | Other diseases of bone and mineral metabolism | ECTS2013

IFITM5 c.−14C>T mutation causes variable type V osteogenesis imperfecta phenotype and decreased COL1A1 expression but increased mineralization by cultured proband osteoblasts

Reich Adi , Bae Alison S , Barnes Aileen M , Cabral Wayne A , Chitayat David , Marini Joan C

Introduction: Osteogenesis imperfecta (OI) is a genetically heterogeneous disorder characterized by bone fragility. OI type V, with autosomal dominant inheritance, is characterized by ossification of the forearm interosseus membrane, radiodense metaphyseal bands, propensity for hyperplastic callus formation, and mesh-like lamellation on bone histology. Type V OI probands are reported to have white sclerae and normal teeth. Recent reports identified the cause of type V OI as a ...